在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

美國KaloBios Pharmaceuticals
Humaneering（TM）是KaloBios制藥的專利治療方法，用于將非人體抗體轉為應用于治療藥物的工程人體抗體。該系統具有保持抗原決定基特異性和提高親和性的優點。KaloBios正在有限的基礎上提供利用humaneering（TM）功能的機會。

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company has multiple programs that were in seven Phase 1 or 2 clinical trials in 2008/09: KB001 is an anti-infective for Pseudomonas aeruginosa infections being tested in cystic fibrosis and in intensive care patients on a ventilator, and KB002 and KB003 are being evaluated in inflammatory conditions, such as rheumatoid arthritis and asthma. KB004 is in preclinical development for oncology, and the company plans to file an IND for it in 1H 2010. The company抯 Humaneering?technology offers advantages over other methods of human antibody creation in terms of immunogenicity, potency, and manufacturing yields. The company is focusing on partnering its clinical-stage programs in 2009 and may grant limited access to its Humaneering?technology platform to select partners.

KaloBios was formed in 2001 and merged in 2004 with Celscia. Since the company抯 founding, it has raised a total of $80 million in four rounds of venture funding with the major shareholders being MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, Mitsubishi UFJ Capital, Genzyme Ventures, Baxter International, Inc., and the Development Bank of Japan. The company is headquartered in South San Francisco, CA and has approximately 50 employees.

?

Mission
Our mission is to become a leading biopharmaceutical company developing and commercializing biotherapies to treat unmet medical needs. We are committed to working to high standards of excellence and integrity to bring improved treatment options to patients, rewarding employment to our employees and significant returns to our stockholders.
?